Effect of vitamin D on pancreas and controlling of T1DM

Effect of vitamin D on pancreatic function and controlling of type 1 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180228038900N2

Enrollment

Registered

2018-07-30

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus. Type 1 diabetes mellitus

Interventions

Type 1 diabetes mellitus children who had been treated with long-acting insulin (glargine) and fast-acting insulin (aspart) based on the Basal Bolus Insulin Protocol (BBIP) in the last five years, wit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children who have been diagnosed with type 1 diabetes mellitus in the last five years and they referred to Endocrinology Clinic of Amirkola Children's Hospital C-peptid above 0.2 nanomol per liter Vitamin D level lower than 30 nano-gram per milliliter Calcium above 8.5 milligram per deciliter

Exclusion criteria

Exclusion criteria: Not modify vitamin D after a course of vitamin D deficiency treatment

Design outcomes

Primary

Measure	Time frame
C-peptide. Timepoint: At the beginning of the study (before intervention) and end of study (9 months after starting treatment). Method of measurement: Blood serum level.;Hemoglobin A1C. Timepoint: At the beginning of the study (before intervention) and end of study (9 months after starting treatment). Method of measurement: Blood serum level.;Total daily dose of Insuline. Timepoint: At the beginning of the study (before intervention) and every 3 months until end of study (9 months after starting treatment). Method of measurement: Question of the parents of patient children (recorded in questionnaire).;Vitamin D. Timepoint: At the beginning of the study (before intervention) and based on vitamin D level, 6 or 8 weeks later and if modified, end of study. Method of measurement: Blood serum level.	—

Measure

Time frame

C-peptide. Timepoint: At the beginning of the study (before intervention) and end of study (9 months after starting treatment). Method of measurement: Blood serum level.;Hemoglobin A1C. Timepoint: At the beginning of the study (before intervention) and end of study (9 months after starting treatment). Method of measurement: Blood serum level.;Total daily dose of Insuline. Timepoint: At the beginning of the study (before intervention) and every 3 months until end of study (9 months after starting treatment). Method of measurement: Question of the parents of patient children (recorded in questionnaire).;Vitamin D. Timepoint: At the beginning of the study (before intervention) and based on vitamin D level, 6 or 8 weeks later and if modified, end of study. Method of measurement: Blood serum level.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Alihanpour Aghamaleki

Babol University of Medical Sciences

m.alijanpour@mubabol.ac.ir+98 11 3234 6963

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026